Prostate Cancer Clinical Trials in Pittsburgh

Showing 241-260 of 381 trials

Analyses of Human Samples Collected in Clinical Trials

NCT00339664

Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes. The purpose of this study is to conduct further analyses on these existing samples from clinical trials that are being performed outside of, but in collaboration with, the National Cancer Institute.

Leukemia, MyeloidNeoplasm MetastasisLeukemia, Lymphoid+1 more

National Cancer Institute (NCI)2,579 participantsStarted Jul 2003

Washington D.C., District of Columbia, United States • Tampa, Florida, United States • Chicago, Illinois, United States +14 more locations

COMPLETEDPhase 355 miles

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy given at the same time as hormone therapy is more effective than chemotherapy given after hormone therapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy given at the same time as hormone therapy with that of chemotherapy given after hormone therapy in treating patients who have prostate cancer.

Prostate Cancer

Radiation Therapy Oncology Group21 participantsStarted Oct 2002

Phoenix, Arizona, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +75 more locations

Analyses of Human Samples Collected in Clinical Trials

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Prostate Cancer Trials in Other Cities

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Other Conditions in Pittsburgh